The estimated Net Worth of Steven H Stein is at least $23.8 Million dollars as of 12 August 2024. Steven Stein owns over 11,608 units of Incyte stock worth over $5,682,394 and over the last 8 years he sold INCY stock worth over $11,119,578. In addition, he makes $7,041,480 as Executive Vice President and Chief Medical Officer at Incyte.
Sign up
Steven Stein INCY stock SEC Form 4 insiders trading
Steven has made over 13 trades of the Incyte stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 11,608 units of INCY stock worth $703,793 on 12 August 2024.
The largest trade he's ever made was selling 36,124 units of Incyte stock on 2 July 2020 worth over $3,874,299. On average, Steven trades about 3,523 units every 52 days since 2016. As of 12 August 2024 he still owns at least 90,011 units of Incyte stock.
You can see the complete history of Steven Stein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Stein biography
Dr. Steven H. Stein M.D., is Executive Vice President, Chief Medical Officer of the Company. He has served as Executive Vice President and Chief Medical Officer since May 2016 and joined Incyte as Senior Vice President and Chief Medical Officer in March 2015. Prior to joining Incyte, from May 2011 to February 2015, he was the Senior Vice President, US Clinical Development & Medical Affairs at Novartis Pharmaceuticals. From February 2004 to April 2011, Dr. Stein was the Vice President, Global Oncology, Clinical Development and the Head of Medicines Development for Hematology and Supportive Care for GlaxoSmithKline. Dr. Stein held a post-doctoral fellowship in hematology/oncology at the University of Pennsylvania from 1998 to 2001, and earned his M.D. from the University of Witwatersrand in Johannesburg, South Africa in 1990.
What is the salary of Steven Stein?
As the Executive Vice President and Chief Medical Officer of Incyte, the total compensation of Steven Stein at Incyte is $7,041,480. There are 1 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.
How old is Steven Stein?
Steven Stein is 53, he's been the Executive Vice President and Chief Medical Officer of Incyte since 2016. There are 19 older and 5 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
What's Steven Stein's mailing address?
Steven's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.
Insiders trading at Incyte
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B..., and Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
What does Incyte do?
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
What does Incyte's logo look like?
Complete history of Steven Stein stock trades at Incyte, Kura Oncology Inc, and Repare Therapeutics
Incyte executives and stock owners
Incyte executives and other stock owners filed with the SEC include:
-
Herve Hoppenot,
Chairman of the Board, President, Chief Executive Officer -
Steven Stein,
Executive Vice President, Chief Medical Officer -
Wenqing Yao,
Executive Vice President, Head of Discovery Chemistry -
Barry Flannelly,
Executive Vice President and General Manager - US -
Christiana Stamoulis,
Chief Financial Officer, Executive Vice President -
Maria Pasquale,
Executive Vice President, General Counsel -
Herve Hoppenot,
Chairman, Pres & CEO -
Paula Swain,
Executive Vice President - Human Resources -
Christiana Stamoulis,
Exec. VP & CFO -
Dr. Steven H. Stein,
Exec. VP & Chief Medical Officer -
Dr. Vijay K. Iyengar M.D.,
Exec. VP of Global Strategy & Corp. Devel. -
Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.,
Exec. VP & GM of North America -
Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA,
Exec. VP & GM of North America -
Julian Baker,
Lead Independent Director -
Paul Clancy,
Independent Director -
Wendy Dixon,
Independent Director -
Jacqualyn Fouse,
Independent Director -
Jean-Jacques Bienaime,
Independent Director -
Paul Friedman,
Independent Director -
Edmund Harrigan,
Independent Director -
Michael Booth,
Vice President - Investor Relations -
Katherine High,
Independent Director -
Vijay Iyengar,
Executive Vice President, Global Strategy and Corporate Development -
Dashyant Dhanak,
Executive Vice President, Chief Scientific Officer -
Thomas Tray,
VP of Fin., Chief Accounting Officer & Controller -
Pamela M. Murphy,
VP of Investor Relations & Corp. Communications -
Maria E. Pasquale,
Exec. VP & Gen. Counsel -
Christine Chiou,
Head of Investor Relations -
Dr. Dashyant Dhanak Ph.D.,
Exec. VP & Chief Scientific Officer -
Michael James Morrissey,
Exec. VP & Head of Global Technical Operations -
Reid M Huber,
EVP, Chief Scientific Officer -
Julian14159, L.P.667, L.P.B...,
-
David W Gryska,
Executive Vice President, CFO -
Paul Trower,
Principal Accounting Officer -
Julianbaker Felixbaker Bros...,
-
Eric H. Siegel,
EVP, General Counsel -
Paul A Brooke,
Director -
Matteo Trotta,
EVP, GM, Dermatology US -
Bros. Advisors Lp14159, L.P...,
-
Bros. Advisors Lp Baker Bro...,
-
Bros. Capital (Gp), Llcbake...,
-
Schutter Richard U De,
Director -
Barry A Ariko,
Director -
Foundation Inc Damial,
10% owner -
Daniel R Tisch,
10% owner -
Julian Baker,
Director -
Biotech Capital Ii Gp Llcba...,
-
James M Daly,
Exec. VP & Chief Comm. Officer -
Brothers Life Sciences Capi...,
-
Laurent Chardonnet,
VP Finance and Treasurer -
John A Keller,
Exec VP & Chief Bus Officer -
Jon S Saxe,
Director -
Biotech Capital (Gp), Llcba...,
-
/ Tisch Capital (Gp), Llcba...,
-
Brothers Life Sciences Capi...,
-
John F Niblack,
Director -
Biotech Capital (Gp), Llcba...,
-
Fred B Craves,
Director -
Biotech Capital Gp Llcbaker...,
-
David C Hastings,
Exec VP & CFO -
Patricia A Schreck,
EVP and General Counsel -
/ Tisch Capital (Gp), Llcba...,
-
Richard S Levy,
EVP, Chief Drug Dev&Medical Of -
Biotech Capital (Gp), Llcba...,
-
Scott W Hurley,
-
Capital (Gp), Llcbaker Feli...,
-
Matthew Emmens,
Director -
/ Tisch Capital (Gp), Llcba...,
-
Capital (Gp), Llcbaker Juli...,
-
Steven M. Friedman,
EVP, Biology & Preclinical Dev -
Bros. Capital (Gp), Llcbake...,
-
Julianbaker Felixbaker Bros...,
-
James S Tisch,
10% owner -
Bros. Capital (Gp), Llcbake...,
-
Brian W Metcalf,
-
Andrew H Tisch,
10% owner -
Michael James Morrissey,
EVP, Head of Tech. Operations -
Thomas J Tisch,
10% owner -
Roy A Whitfield,
Director -
Capital (Gp), Llcbaker Juli...,
-
Biotech Capital Ii Gp Llcba...,
-
Brothers Life Sciences Capi...,
-
Bonnie J Tisch,
10% owner -
Bros. Advisors Lp667, L.P.B...,
-
Jonathan Elliott Dickinson,
EVP, General Manager, Europe -
Bros. Advisors Lp Baker Bro...,
-
Thomas Tray,
Principal Accounting Officer -
Otis W Brawley,
Director -
Bros. Advisors Lp667, L.P.B...,
-
Pablo J Cagnoni,
President, R&D -
Susanne Schaffert,
Director -
Sheila A. Denton,
EVP & General Counsel